192 related articles for article (PubMed ID: 38559969)
1. EIDD-1931 Treatment Tweaks CYP3A4 and CYP2C8 in Arthritic Rats to Expedite Drug Interaction: Implication in Oral Therapy of Molnupiravir.
Bhardwaj M; Kour D; Rai G; Bhattacharya S; Manhas D; Vij B; Kumar A; Mukherjee D; Ahmed Z; Gandhi SG; Nandi U
ACS Omega; 2024 Mar; 9(12):13982-13993. PubMed ID: 38559969
[TBL] [Abstract][Full Text] [Related]
2. Impact of Disease States on the Oral Pharmacokinetics of EIDD-1931 (an Active Form of Molnupiravir) in Rats for Implication in the Dose Adjustment.
Bhardwaj M; Gour A; Ahmed A; Dhiman S; Manhas D; Khajuria P; Wazir P; Mukherjee D; Nandi U
Mol Pharm; 2023 Sep; 20(9):4597-4610. PubMed ID: 37527414
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
Paludetto MN; Kurkela M; Kahma H; Backman JT; Niemi M; Filppula AM
Drug Metab Dispos; 2023 Mar; 51(3):293-305. PubMed ID: 36446607
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Herb-Drug Interaction of Synacinn™ and Individual Biomarker through Cytochrome 450 Inhibition Assay.
Ab Rahman NS; Abd Majid FA; Abd Wahid ME; Zainudin AN; Zainol SN; Ismail HF; Wong TS; Tiwari NK; Giri S; Bhargava V
Drug Metab Lett; 2018; 12(1):62-67. PubMed ID: 29542427
[TBL] [Abstract][Full Text] [Related]
5. Predictive In Vitro-In Vivo Extrapolation for Time Dependent Inhibition of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and CYP2D6 Using Pooled Human Hepatocytes, Human Liver Microsomes, and a Simple Mechanistic Static Model.
Ramsden D; Perloff ES; Whitcher-Johnstone A; Ho T; Patel R; Kozminski KD; Fullenwider CL; Zhang JG
Drug Metab Dispos; 2022 Feb; 50(2):114-127. PubMed ID: 34789487
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Derks M; Fowler S; Kuhlmann O
Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
[TBL] [Abstract][Full Text] [Related]
7. An In Vitro and In Vivo Evaluation of the Effect of Relacorilant on the Activity of Cytochrome P450 Drug Metabolizing Enzymes.
Custodio JM; Donaldson KM; Hunt HJ
J Clin Pharmacol; 2021 Feb; 61(2):244-253. PubMed ID: 32869328
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Jaakkola T; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):44-51. PubMed ID: 16867170
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450-mediated herb-drug interaction (HDI) of Polygonum multiflorum Thunb. based on pharmacokinetic studies and in vitro inhibition assays.
Xing Y; Yu Q; Zhou L; Cai W; Zhang Y; Bi Y; Zhang Y; Fu Z; Han L
Phytomedicine; 2023 Apr; 112():154710. PubMed ID: 36805481
[TBL] [Abstract][Full Text] [Related]
10. Characterisation of cytochrome P450 isoenzyme activity in sheep liver and placental microsomes.
Meakin AS; Amirmostofian M; Darby JR; Holman SL; Morrison JL; Wiese MD
Placenta; 2023 Jan; 131():82-89. PubMed ID: 36527743
[TBL] [Abstract][Full Text] [Related]
11. ZY12201, A Potent TGR5 Agonist: Identification of a Novel Pan CYP450 Inhibitor Tool Compound for In-Vitro Assessment.
Giri P; Gupta L; Rathod A; Joshi V; Giri S; Patel N; Agarwal S; R Jain M
Drug Metab Lett; 2022 Mar; ():. PubMed ID: 35293300
[TBL] [Abstract][Full Text] [Related]
12. In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450.
McCormick A; Swaisland H; Reddy VP; Learoyd M; Scarfe G
Xenobiotica; 2018 Jun; 48(6):555-564. PubMed ID: 28657402
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Gupta P; Alvey C; Wang R; Dowty ME; Fahmi OA; Walsky RL; Riese RJ; Krishnaswami S
Br J Clin Pharmacol; 2012 Jul; 74(1):109-15. PubMed ID: 22233204
[TBL] [Abstract][Full Text] [Related]
14. Direct inhibition of Re Du Ning Injection and its active compounds on human liver cytochrome P450 enzymes by a cocktail method.
Kang D; Geng T; Lian Y; Li Y; Ding G; Huang W; Ma S; Wang Z; Ma Z; Xiao W
Biomed Chromatogr; 2017 Jul; 31(7):. PubMed ID: 27891633
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
16. An automated cocktail method for in vitro assessment of direct and time-dependent inhibition of nine major cytochrome P450 enzymes - application to establishing CYP2C8 inhibitor selectivity.
Kahma H; Aurinsalo L; Neuvonen M; Katajamäki J; Paludetto MN; Viinamäki J; Launiainen T; Filppula AM; Tornio A; Niemi M; Backman JT
Eur J Pharm Sci; 2021 Jul; 162():105810. PubMed ID: 33753217
[TBL] [Abstract][Full Text] [Related]
17. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic Roux-en-Y gastric bypass surgery influenced pharmacokinetics of several drugs given as a cocktail with the highest impact observed for CYP1A2, CYP2C8 and CYP2E1 substrates.
Puris E; Pasanen M; Ranta VP; Gynther M; Petsalo A; Käkelä P; Männistö V; Pihlajamäki J
Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):123-132. PubMed ID: 30916845
[TBL] [Abstract][Full Text] [Related]
19. Oxidative metabolism of 5-methoxy-N,N-diisopropyltryptamine (Foxy) by human liver microsomes and recombinant cytochrome P450 enzymes.
Narimatsu S; Yonemoto R; Saito K; Takaya K; Kumamoto T; Ishikawa T; Asanuma M; Funada M; Kiryu K; Naito S; Yoshida Y; Yamamoto S; Hanioka N
Biochem Pharmacol; 2006 Apr; 71(9):1377-85. PubMed ID: 16510126
[TBL] [Abstract][Full Text] [Related]
20. Assessment of induction of cytochrome P450 by NO-1886 (ibrolipim), a lipoprotein lipase-promoting agent, in primary cultures of human hepatocytes and in female rat liver.
Morioka Y; Nishimura M; Imai T; Suzuki S; Harada M; Satoh T; Naito S
Drug Metab Pharmacokinet; 2006 Feb; 21(1):19-28. PubMed ID: 16547390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
